CLDI Key Statistics, Chart & Performance
The current stock price of CLDI is 1.24 USD. In the past month the price decreased by -16.22%. In the past year, price decreased by -92.29%.
CLDI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About CLDI
Company Profile
Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2021-09-10. The firm is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. The company is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
Company Info
CALIDI BIOTHERAPEUTICS INC
4475 Executive Drive, Suite 200
San Diego CALIFORNIA US
Employees: 28
Phone: 18587949600
CALIDI BIOTHERAPEUTICS INC / CLDI FAQ
What does CALIDI BIOTHERAPEUTICS INC do?
Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2021-09-10. The firm is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. The company is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
Can you provide the latest stock price for CALIDI BIOTHERAPEUTICS INC?
The current stock price of CLDI is 1.24 USD. The price decreased by -3.88% in the last trading session.
Does CALIDI BIOTHERAPEUTICS INC pay dividends?
CLDI does not pay a dividend.
How is the ChartMill rating for CALIDI BIOTHERAPEUTICS INC?
CLDI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists CLDI stock?
CLDI stock is listed on the NYSE Arca exchange.
Can you provide the ownership details for CLDI stock?
You can find the ownership structure of CALIDI BIOTHERAPEUTICS INC (CLDI) on the Ownership tab.
CLDI Technical Analysis
CLDI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CLDI. CLDI may be in some trouble as it scores bad on both profitability and health.
CLDI Financial Highlights
Over the last trailing twelve months CLDI reported a non-GAAP Earnings per Share(EPS) of -12.48. The EPS increased by 88.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -212.3% | ||
| ROE | -1125.4% | ||
| Debt/Equity | 0.47 |